Cystic Fibrosis Therapeutics Market - Global Market Share, Trends, Analysis and Forecasts, 2023 - 2032
The anticipated value of the global cystic fibrosis treatments market in 2021 was $5.6 billion, and it is projected to increase at a CAGR of 15% during the forecast period 2023 to 2032.
The increasing number of patients with cystic fibrosis, high prevalence in the pediatric and adult population, and increasing research & development spending are dynamically shaping the global cystic fibrosis therapeutics market. Cystic fibrosis is a hereditary disorder wherein the cystic fibrosis transmembrane conductance regulator (CFTR) protein becomes dysfunctional due to CFTR gene mutation and affects the production of mucus, sweat, and digestive juices.
The severity of the disease varies from person to person and thus demands individual attention and treatment. This has encouraged research & development activities across the world for the development of improved drugs and treatment methods. The global cystic fibrosis market is anticipated to grow at a healthy rate during the forecast period.
North America contributed the largest share to the global cystic fibrosis therapeutics market in 2019 and is anticipated to be the dominating geography throughout the forecast period. The presence of global players, sophisticated healthcare infrastructure, an increasing number of cystic fibrosis patients, and focused research & development activities are the major attributes contributing towards the growth of cystic fibrosis therapeutics market. Asia Pacific cystic fibrosis therapeutics market is anticipated to witness lucrative growth during the forecast period owing to increasing healthcare expenditure and expansion of medical devices and pharmaceutical manufacturing industries.
The report titled “Cystic Fibrosis Therapeutics Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is a historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide a company overview and market outlook for leading players in the global cystic fibrosis therapeutics market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, Novartis International AG reported revenues of USD 47.4 billion in 2019 and the product segment analysis of the company indicates that the Innovative Medicines business segment of the company dominated revenue in 2019.
The global cystic fibrosis therapeutics market is segmented based on drug class, method of administration, and geography. Based on drug class, the global Cystic Fibrosis Therapeutics market is segmented into pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. Based on the method of administration, the global Cystic Fibrosis Therapeutics market is segmented into oral drugs and inhaled drugs. Based on geography, the global Cystic Fibrosis Therapeutics market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The study provides an in-depth analysis of prominent players holding the majority share of the global market with a focus on all operating business segments and would identify the segment of the company focusing on cystic fibrosis therapeutics. Further, the market share of prominent companies in the global cystic fibrosis therapeutics market would also be estimated. For instance, Novartis International AG operates through two business divisions namely Innovative Medicines, and Sandoz. The cystic fibrosis products are delivered under the Respiratory, business segment of the Innovative Medicines business division of the company with a revenue contribution of US$ 1,825 million in 2019.
The research takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the cystic fibrosis therapeutics companies. Furthermore, the global cystic fibrosis therapeutics market study engulfs the participants engaged throughout the supply chain and value chain of the market, along with their contribution. The product portfolio would focus on all the products under the cystic fibrosis therapeutics market business segment of the company. Similarly, the recent development section would focus on the latest developments of the company such as strategic alliances and partnerships, merger and acquisition, a new product launched, and geographic expansion in the global cystic fibrosis therapeutics market.
Major players operating the global cystic fibrosis therapeutics market include AbbVie Inc., Allergan Plc, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Novartis International AG, Pharmaxis Ltd., PTC Therapeutics, and Vertex Pharmaceuticals, Inc.
Market Segmentation:
By Drug Class
- Pancreatic enzyme supplements
- Mucolytics
- Bronchodilators
- CFTR Modulators
By Route of Administration
Based On Geography
-
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Brazil
- Rest of South America
